Skip Nav Destination
Subtype-specific therapy for DLBCL: are we there yet?
Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model
Issue Archive
October 15 2015
Table of Contents
INSIDE BLOOD COMMENTARIES
INSIDE BLOOD COMMENTARY
Subtype-specific therapy for DLBCL: are we there yet?
Clinical Trials & Observations
REVIEW ARTICLE
CLINICAL TRIALS AND OBSERVATIONS
Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation
CME
Clinical Trials & Observations
Francesca Fioredda,Simona Iacobelli,Anja van Biezen,Bobby Gaspar,Phil Ancliff,Jean Donadieu,Mahmoud Aljurf,Christina Peters,Michaela Calvillo,Susanne Matthes-Martin,Giuseppe Morreale,Nelleke van ’t Veer-Tazelaar,Liesbeth de Wreede,Amal Al Seraihy,Akif Yesilipek,Alain Fischer,Marc Bierings,Gulyuz Ozturk,Owen Smith,Paul Veys,Per Ljungman,Régis Peffault de Latour,José Sánchez de Toledo Codina,Reuven Or,Arnold Ganser,Boris Afanasyev,Robert Wynn,Krzysztof Kalwak,Judith Marsh,Carlo Dufour,on behalf of the Severe Aplastic Anemia the Inborn Error, and the Pediatric Disease Working Parties of the European Society for Blood and Bone Marrow Transplantation (EBMT) and Stem Cell Transplant for Immunodeficiencies in Europe (SCETIDE)
Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL
Clinical Trials & Observations
Fritz Offner,Olga Samoilova,Evgenii Osmanov,Hyeon-Seok Eom,Max S. Topp,João Raposo,Viacheslav Pavlov,Deborah Ricci,Shalini Chaturvedi,Eugene Zhu,Helgi van de Velde,Christopher Enny,Aleksandra Rizo,Burhan Ferhanoglu
LYMPHOID NEOPLASIA
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia
Clinical Trials & Observations
Brief Report
Davide Rossi,Lodovico Terzi-di-Bergamo,Lorenzo De Paoli,Michaela Cerri,Guido Ghilardi,Annalisa Chiarenza,Pietro Bulian,Carlo Visco,Francesca R. Mauro,Fortunato Morabito,Agostino Cortelezzi,Francesco Zaja,Francesco Forconi,Luca Laurenti,Ilaria Del Giudice,Massimo Gentile,Iolanda Vincelli,Marina Motta,Marta Coscia,Gian Matteo Rigolin,Alessandra Tedeschi,Antonino Neri,Roberto Marasca,Omar Perbellini,Carol Moreno,Giovanni Del Poeta,Massimo Massaia,Pier Luigi Zinzani,Marco Montillo,Antonio Cuneo,Valter Gattei,Robin Foà,Gianluca Gaidano
MYELOID NEOPLASIA
RED CELLS, IRON, AND ERYTHROPOIESIS
THROMBOSIS AND HEMOSTASIS
Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking
James R. Byrnes,Cédric Duval,Yiming Wang,Caroline E. Hansen,Byungwook Ahn,Micah J. Mooberry,Martha A. Clark,Jill M. Johnsen,Susan T. Lord,Wilbur A. Lam,Joost C. M. Meijers,Heyu Ni,Robert A. S. Ariëns,Alisa S. Wolberg
Predicting recurrence after unprovoked venous thromboembolism: prospective validation of the updated Vienna Prediction Model
Clinical Trials & Observations
Brief Report
VASCULAR BIOLOGY
BLOOD WORK
CORRESPONDENCE
Gray platelet syndrome can mimic autoimmune lymphoproliferative syndrome
Anne Rensing-Ehl,Ulrich Pannicke,Stefanie-Yvonne Zimmermann,Myriam Ricarda Lorenz,Benedicte Neven,Ilka Fuchs,Ulrich Salzer,Carsten Speckmann,Anne Strauss,Eberhard Maaβ,Benedicte Collet,Anselm Enders,Remi Favier,Marie Christine Alessi,Frederic Rieux-Laucat,Barbara Zieger,Klaus Schwarz,Stephan Ehl
CONTINUING MEDICAL EDUCATION (CME) QUESTIONS
-
Cover Image
Cover Image
![issue cover]()
Dendritic cell–specific intercellular adhesion molecule-3–grabbing nonintegrin (DC-SIGN) expressing M2 macrophages triggered B-cell receptor signaling in follicular lymphoma. The myeloid markers DC-SIGN (green) and CD68 (blue) were used to characterize monocyte-derived M2 macrophages. The nucleus was stained with SytoxBlue (white). Original magnification ×63. See the article by Amin et al on page 1911.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkAdvertising
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
